Egnach, October 3, 2025 – Resaphene Suisse AG announces the market introduction of the new tinniwell app with external in-ear headphones for the 1st quarter of 2026. This will make the clinically proven tinnitus therapy available for the first time as a mobile, app-based solution.

"With the tinniwell app, we create a completely new flexibility for patients. Our therapy can be applied anytime and anywhere – simply via the smartphone and in-ears," explains Anke Rauterkus, CEO of Resaphene Suisse AG.

At the same time, Resaphene Suisse AG is preparing the listing as a Digital Health Application (DiGA) with the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. Inclusion in the DiGA directory would enable millions of legally insured tinnitus patients to receive the tinniwell app on prescription in the future.

Revenue Expectations

Resaphene Suisse AG expects that with the introduction of the app and a successful DiGA listing, significant revenue growth will be achieved. Already in the first year after market launch, a revenue volume in the mid double-digit million range is expected. In the medium to long term, the company anticipates a three-digit million potential in the German market through reimbursement under statutory health insurance.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland

T. +41 71 510 07 24
a.rauterkus@resaphene.ch